RATIONALE: Pulmonary arterial hypertension (PAH) is an incurable disease associated with viral infections and connective tissue diseases. The relationship between inflammation and disease pathogenesis in these disorders remains poorly understood. OBJECTIVE: To determine whether immune dysregulation due to absent T-cell populations directly contributes to the development of PAH. METHODS AND RESULTS: Vascular endothelial growth factor receptor 2 (VEGFR2) blockade induced significant pulmonary endothelial apoptosis in T-cell-deficient rats but not in immune-reconstituted (IR) rats. T cell-lymphopenia in association with VEGFR2 blockade resulted in periarteriolar inflammation with macrophages, and B cells even prior to vascular remodeling and elevated pulmonary pressures. IR prevented early inflammation and attenuated PAH development. IR with either CD8 T cells alone or with CD4-depleted spleen cells was ineffective in preventing PAH, whereas CD4-depleting immunocompetent euthymic animals increased PAH susceptibility. IR with either CD4(+)CD25(hi) or CD4(+)CD25(-) T cell subsets prior to vascular injury attenuated the development of PAH. IR limited perivascular inflammation and endothelial apoptosis in rat lungs in association with increased FoxP3(+), IL-10- and TGF-β-expressing CD4 cells, and upregulation of pulmonary bone morphogenetic protein receptor type 2 (BMPR2)-expressing cells, a receptor that activates endothelial cell survival pathways. CONCLUSIONS: PAH may arise when regulatory T-cell (Treg) activity fails to control endothelial injury. These studies suggest that regulatory T cells normally function to limit vascular injury and may protect against the development of PAH.
RATIONALE: Pulmonary arterial hypertension (PAH) is an incurable disease associated with viral infections and connective tissue diseases. The relationship between inflammation and disease pathogenesis in these disorders remains poorly understood. OBJECTIVE: To determine whether immune dysregulation due to absent T-cell populations directly contributes to the development of PAH. METHODS AND RESULTS:Vascular endothelial growth factor receptor 2 (VEGFR2) blockade induced significant pulmonary endothelial apoptosis in T-cell-deficient rats but not in immune-reconstituted (IR) rats. T cell-lymphopenia in association with VEGFR2 blockade resulted in periarteriolar inflammation with macrophages, and B cells even prior to vascular remodeling and elevated pulmonary pressures. IR prevented early inflammation and attenuated PAH development. IR with either CD8 T cells alone or with CD4-depleted spleen cells was ineffective in preventing PAH, whereas CD4-depleting immunocompetent euthymic animals increased PAH susceptibility. IR with either CD4(+)CD25(hi) or CD4(+)CD25(-) T cell subsets prior to vascular injury attenuated the development of PAH. IR limited perivascular inflammation and endothelial apoptosis in rat lungs in association with increased FoxP3(+), IL-10- and TGF-β-expressing CD4 cells, and upregulation of pulmonary bone morphogenetic protein receptor type 2 (BMPR2)-expressing cells, a receptor that activates endothelial cell survival pathways. CONCLUSIONS: PAH may arise when regulatory T-cell (Treg) activity fails to control endothelial injury. These studies suggest that regulatory T cells normally function to limit vascular injury and may protect against the development of PAH.
Authors: L Taraseviciene-Stewart; Y Kasahara; L Alger; P Hirth; G Mc Mahon ; J Waltenberger; N F Voelkel; R M Tuder Journal: FASEB J Date: 2001-02 Impact factor: 5.191
Authors: M Fujita; J M Shannon; C G Irvin; K A Fagan; C Cool; A Augustin; R J Mason Journal: Am J Physiol Lung Cell Mol Physiol Date: 2001-01 Impact factor: 5.464
Authors: O Benveniste; P Chérin; T Maisonobe; R Merat; O Chosidow; L Mouthon; L Guillevin; A Flahault; M C Burland; D Klatzmann; S Herson; O Boyer Journal: J Immunol Date: 2001-09-15 Impact factor: 5.422
Authors: Moira Hagen; Karen Fagan; Wolfgang Steudel; Michelle Carr; Kirk Lane; David M Rodman; James West Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-02-23 Impact factor: 5.464
Authors: Machteld M Tiemessen; Ann L Jagger; Hayley G Evans; Martijn J C van Herwijnen; Susan John; Leonie S Taams Journal: Proc Natl Acad Sci U S A Date: 2007-11-27 Impact factor: 11.205
Authors: Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls Journal: Eur Respir J Date: 2012-06-27 Impact factor: 16.671
Authors: Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-02-03 Impact factor: 5.464
Authors: Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas Journal: Am J Respir Cell Mol Biol Date: 2014-09 Impact factor: 6.914
Authors: Jenny Y Chen; Megan Griffiths; Jun Yang; Melanie K Nies; Rachel L Damico; Catherine E Simpson; R Dhananjay Vaidya; Stephanie Brandal; D Dunbar Ivy; Eric D Austin; William C Nichols; Michael W Pauciulo; Katie Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; Allen D Everett Journal: J Pediatr Date: 2020-08 Impact factor: 4.406
Authors: Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Rasa Tamosiuniene; Olga Manouvakhova; Paul Mesange; Toshie Saito; Jin Qian; Mrinmoy Sanyal; Yu-Chun Lin; Linh P Nguyen; Amir Luria; Allen B Tu; Joshua M Sante; Marlene Rabinovitch; Desmond J Fitzgerald; Brian B Graham; Aida Habtezion; Norbert F Voelkel; Laure Aurelian; Mark R Nicolls Journal: Circ Res Date: 2018-03-15 Impact factor: 17.367